Monday, July 29, 2024
4:30 PM – 5:30 PM UTC | 6:30 PM – 7:30 PM CEST | 12:30 PM – 1:30 PM EDT
Agenda:
- Introduction by Session Chair – Prof Maryam Lustberg
- Overview of oral targeted therapies for metastatic hormone receptor positive breast cancer – Dr Aditya Bardia
- Management of oral targeted therapy toxicities in breast cancer – Prof Maryam Lustberg
- Patient experience – closing the loop – Abigail Johnston (Patient Partner)
- Panel Discussion and Q&A
Learning Objectives:
- Improve the understanding of clinicians regarding prescribing oral targeted therapies for hormone receptor positive metastatic breast cancer.
- Discuss common toxicities for oral targeted therapies and how to manage them.
- Understanding the patient experience and how it impacts quality of life, adherence, and disease outcomes; and taking a shared decision approach.
Sponsored by Menarini Group/Stemline Therapeutics
![Menarini Group / Stemline Therapeutics logo](https://mascc.org/wp-content/uploads/2024/07/MenariniStemline-300x100.png)
Speakers:
![Maryam Lustberg](https://mascc.org/wp-content/uploads/2022/06/lustberg_2022.jpg)
Prof Maryam Lustberg
Session Chair
![](https://mascc.org/wp-content/uploads/2024/07/aditya-bardia-450x450-1.jpg)
Dr Aditya Bardia
![Abigail Johnston](https://mascc.org/wp-content/uploads/2024/07/abigail-johnston-450x450-1.jpg)
Abigail Johnston
(Patient Partner)